Cargando…

Repurposing FDA approved drugs as possible anti-SARS-CoV-2 medications using ligand-based computational approaches: sum of ranking difference-based model selection

The worldwide burden of coronavirus disease 2019 (COVID-19) is still unremittingly prevailing, with more than 440 million infections and over 5.9 million deaths documented so far since the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pandemic. The non-availability of treatment furthe...

Descripción completa

Detalles Bibliográficos
Autores principales:	De, Priyanka, Kumar, Vinay, Kar, Supratik, Roy, Kunal, Leszczynski, Jerzy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171098/ https://www.ncbi.nlm.nih.gov/pubmed/35692512 http://dx.doi.org/10.1007/s11224-022-01975-3

Ejemplares similares

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

Hydrogel-Based Pre-Clinical Evaluation of Repurposed FDA-Approved Drugs for AML
por: James, Jenna R., et al.
Publicado: (2023)

Impact of Pharmaceuticals on the Environment: Risk Assessment Using QSAR Modeling Approach
por: Kar, Supratik, et al.
Publicado: (2018)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle
por: Huang, Yue, et al.
Publicado: (2022)

Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?
por: Zaidi, Asifa, et al.
Publicado: (2015)

Repurposing of existing FDA approved drugs for Neprilysin inhibition: An in-silico study
por: Sankhe, Runali, et al.
Publicado: (2021)

Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
por: Bibby, Becky A. S., et al.
Publicado: (2021)

REPURPOSING OF FDA APPROVED COMPOUNDS TO INHIBIT OSM/OSMR SIGNALING IN GLIOBLASTOMA
por: Lotfipour, Farzaneh, et al.
Publicado: (2023)

Repurposing FDA-approved drugs as FXR agonists: a structure based in silico pharmacological study
por: Jose, Sandra, et al.
Publicado: (2023)

Therapeutics for COVID-19: from computation to practices—where we are, where we are heading to
por: Ojha, Probir Kumar, et al.
Publicado: (2020)

Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
por: Kim, Kevin, et al.
Publicado: (2015)

Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae
por: Abutaleb, Nader S., et al.
Publicado: (2021)

Impact of Nutrition or FDA-Approved Medicine Repurposing on Metabolic Syndrome and Diabetic Complications
por: Cai, Lu
Publicado: (2023)

Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with Repurposing Potential
por: Lo, Yu-Chen, et al.
Publicado: (2017)

Exploration of Computational Approaches to Predict the Toxicity of Chemical Mixtures
por: Kar, Supratik, et al.
Publicado: (2019)

Editorial note: repurposing FDA approved drugs as FXR agonists: a structure based in silico pharmacological study
Publicado: (2022)

Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection
por: Benedict, Ashwini, et al.
Publicado: (2015)

Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
por: Sirohi, Devika, et al.
Publicado: (2017)

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020)

Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19)
por: De Vita, Simona, et al.
Publicado: (2020)

Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
por: Jones, Dylan, et al.
Publicado: (2022)

Possible FDA-approved drugs to treat Ebola virus infection
por: Yuan, Shu
Publicado: (2015)

Repurposing of FDA-Approved NSAIDs for DPP-4 Inhibition as an Alternative for Diabetes Mellitus Treatment: Computational and in Vitro Study
por: Chittepu, Veera C. S. R., et al.
Publicado: (2019)

Computational Insights and Virtual Screening of Repurposed FDA-Approved Drug Against SARS-CoV-2 Protease
por: Joel, C., et al.
Publicado: (2023)

Disruption of Irisin Dimerization by FDA-Approved Drugs: A Computational Repurposing Approach for the Potential Treatment of Lipodystrophy Syndromes
por: Flori, Lorenzo, et al.
Publicado: (2023)

Repurposing the FDA-Approved Pinworm Drug Pyrvinium as a Novel Chemotherapeutic Agent for Intestinal Polyposis
por: Li, Bin, et al.
Publicado: (2014)

QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics
por: O’Reilly, Paul G., et al.
Publicado: (2016)

Large-Scale Drug Screen Identifies FDA-Approved Drugs for Repurposing in Sickle-Cell Disease
por: Cannon, Matthew, et al.
Publicado: (2020)

FDA Approved Drugs Repurposing of Toll-Like Receptor4 (TLR4) Candidate for Neuropathy
por: Zali, Hakimeh, et al.
Publicado: (2019)

Repurposing FDA Approved Drugs as JNK3 Inhibitor for Prevention of Neuroinflammation Induced by MCAO in Rats
por: Zulfiqar, Zikra, et al.
Publicado: (2020)

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
por: Xu, Chenshu, et al.
Publicado: (2020)

Geroscience‐guided repurposing of FDA‐approved drugs to target aging: A proposed process and prioritization
por: Kulkarni, Ameya S., et al.
Publicado: (2022)

Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2
por: Ku, Keun Bon, et al.
Publicado: (2020)

Pharmacophore-based approaches in the rational repurposing technique for FDA approved drugs targeting SARS-CoV-2 M(pro)
por: Balaramnavar, Vishal M., et al.
Publicado: (2020)

A Transcriptomics-Based Bioinformatics Approach for Identification and In Vitro Screening of FDA-Approved Drugs for Repurposing against Dengue Virus-2
por: Punekar, Madhura, et al.
Publicado: (2022)

Bayesian rank-based hypothesis testing for the rank sum test, the signed rank test, and Spearman's ρ
por: van Doorn, J., et al.
Publicado: (2020)

The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.
por: Olivier, Timothée, et al.
Publicado: (2022)

Insight into the optoelectronic properties of designed solar cells efficient tetrahydroquinoline dye-sensitizers on TiO(2)(101) surface: first principles approach
por: Roy, Juganta K., et al.
Publicado: (2018)

Optoelectronic Properties of C(60) and C(70) Fullerene Derivatives: Designing and Evaluating Novel Candidates for Efficient P3HT Polymer Solar Cells
por: Roy, Juganta K., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rdi7er4ppd23e16ecc4t0o2ml9